Nurix Therapeutics Advances Promising Targeted Protein Modulation Pipeline and Outlines 2023 Strategic Priorities Portfolio News / Karina Tin January 9, 2023 Nurix Therapeutics Advances Promising Targeted Protein Modulation Pipeline and Outlines 2023 Strategic Priorities Read More »
Synthekine Secures $100 Million Series C Financing to Advance Pipeline of Engineered Cytokine Therapeutics Portfolio News / Karina Tin January 6, 2023 Synthekine Secures $100 Million Series C Financing to Advance Pipeline of Engineered Cytokine Therapeutics Read More »
Carmot Therapeutics Launches Spin-Off, Kimia Therapeutics, to Focus on Metabolic Disease Portfolio News / Karina Tin January 5, 2023 Carmot Therapeutics Launches Spin-Off, Kimia Therapeutics, to Focus on Metabolic Disease Read More »
eFFECTOR Therapeutics Provides Positive Clinical Data Update for Zotatifin and General Corporate Update Portfolio News / Karina Tin January 5, 2023 eFFECTOR Therapeutics Provides Positive Clinical Data Update for Zotatifin and General Corporate Update Read More »
Remix Therapeutics Appoints Christopher Bowden, M.D., as Chief Medical Officer Portfolio News / Karina Tin January 5, 2023 Remix Therapeutics Appoints Christopher Bowden, M.D., as Chief Medical Officer Read More »
ORIC Pharmaceuticals Announces Clinical Development Collaboration with Pfizer for ORIC-533 in Multiple Myeloma and Concurrent $25 Million Equity Investment by Pfizer Portfolio News / Karina Tin December 21, 2022 ORIC Pharmaceuticals Announces Clinical Development Collaboration with Pfizer for ORIC-533 in Multiple Myeloma and Concurrent $25 Million Equity Investment by Pfizer Read More »
Revolution Medicines Announces Publication Describing Design and Synthesis of RMC-5552, a First-in-Class, Bi-Steric mTORC1-Selective Inhibitor Portfolio News / Karina Tin December 19, 2022 Revolution Medicines Announces Publication Describing Design and Synthesis of RMC-5552, a First-in-Class, Bi-Steric mTORC1-Selective Inhibitor Read More »
Nurix Therapeutics Announces Clearance of Investigational New Drug Application for NX-5948 Supporting Plans to Expand Enrollment to U.S. Clinical Sites Portfolio News / Karina Tin December 15, 2022 Nurix Therapeutics Announces Clearance of Investigational New Drug Application for NX-5948 Supporting Plans to Expand Enrollment to U.S. Clinical Sites Read More »
ORIC Pharmaceuticals Presents Preclinical Data Demonstrating ORIC-533 as a Potential Best-in-Class CD73 Inhibitor at the 64th American Society of Hematology (ASH) Annual Meeting Portfolio News / Karina Tin December 13, 2022 ORIC Pharmaceuticals Presents Preclinical Data Demonstrating ORIC-533 as a Potential Best-in-Class CD73 Inhibitor at the 64th American Society of Hematology (ASH) Annual Meeting Read More »
NGM Bio Gives Presentation Featuring Preclinical Characterization of NGM936 at 2022 ASH Annual Meeting Portfolio News / Karina Tin December 12, 2022 NGM Bio Gives Presentation Featuring Preclinical Characterization of NGM936 at 2022 ASH Annual Meeting Read More »